Baudax Bio, Inc. Banner Image

Baudax Bio, Inc.

  • Ticker BXRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Baudax Bio, Inc. Logo Image
  • 11-50 Employees
  • Based in Malvern, Pennsylvania
Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The Company’s first commercial product, ANJESO®, had its New Drug Application approved by FDA on February 20, 2020 for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfullyMore completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. As a non-opioid, IV meloxicam has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential while maintaining meaningful analgesic effects for relief of pain.
4.8 / 5.0 (310)

Baudax Bio, Inc. reports have an aggregate usefulness score of 4.8 based on 310 reviews.

Baudax Bio, Inc.

Most Recent Annual Report

Baudax Bio, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Baudax Bio, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!